Items where Subject is "RM300 Drugs and their actions"

2013

1. Frogley, C., Anagnostakis, K., Mitchell, S., Mason, F., Taylor, D., Dickens, G. and Picchioni, M. (2013) A case series of clozapine for borderline personality disorder. Annals of Clinical Psychiatry. 25(2), pp. 125-134. 1040-1237.

2012

1. Frogley, C., Taylor, D., Dickens, G. and Picchioni, M. (2012) A systematic review of the evidence of clozapine's anti-aggresive effects. The International Journal of Neuropsychopharmacology. 15(09), pp. 1351-1371. 1469-5111.

1999

1. Raleigh, S. M., Wanogho, E., Burke, M. D. and Patterson, L. H. (1999) Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica. 29(11), pp. 1115-1122. 0049-8254.

1998

1. Patterson, L. H. and Raleigh, S. M. (1998) Reductive metabolism: its application in prodrug activation. In: Gooderham, N. J. (ed.) Drug Metabolism: Towards the Next Millenium. Amsterdam: IOS Press. pp. 72-80.
2. Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R. and Patterson, L. H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. International Journal of Radiation Oncology, Biology, Physics. 42(4), pp. 763-767. 0360-3016.